Quote:Median overall survival was 20.9 months with the best treatment (regorafenib, ipilimumab, nivolumab) hitting 27.5 months.
Maybe not a fair comparison? Bot/Bal was used later line, including patients who failed prior CTLA-4/PD-(L)1 or combination. Perhaps a comparison with TAS-102+ bev or fruquintinib monotherapy mOS of 10-14 months.
Not trying to pump bot/bal (just keeping an eye out for possible competitors) but France has granted it fully reimbursed compassionate use for MSS mcrc and more recently ovarian cancer and soft tissue sarcomas.